Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
32,659
Total Claims
$2.7M
Drug Cost
2,190
Beneficiaries
$1,217
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,961 Nephrology providers
-5%
Cost per patient vs peers
$1,217 vs $1,283 avg
+30%
Brand preference vs peers
11.6% vs 9.0% avg
Opioid Prescribing
0.2%
Opioid Rate
54
Opioid Claims
$248
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,784 claims · $2.2M
Generic: 28,774 claims · $456K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 1,306 | $836K |
| Amikacin Liposomal/Neb.Accessr | 15 | $244K |
| Sitagliptin Phosphate | 258 | $158K |
| Semaglutide | 102 | $114K |
| Empagliflozin | 142 | $82K |
| Insulin Glargine,hum.Rec.Anlog | 105 | $73K |
| Insulin Aspart | 113 | $61K |
| Mirabegron | 144 | $60K |
| Cinacalcet Hcl | 653 | $57K |
| Insulin Degludec | 31 | $53K |
| Linagliptin | 89 | $53K |
| Potassium Chloride | 2,024 | $50K |
| Bumetanide | 1,306 | $46K |
| Insulin Detemir | 90 | $45K |
| Dulaglutide | 36 | $43K |
Prescribing Profile
Patient Profile
73
Avg Age
56%
Female
2.32
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About